[ad_1]
Original title: The production capacity of China’s new crown vaccine will reach 610 million doses by the end of the year. Cost prices are non-profit
“It is estimated that by the end of this year, the annual production capacity of the new Chinese crown vaccine will reach 610 million doses. Next year, the annual production capacity of the new Chinese crown vaccine will be will effectively expand on this basis to effectively ensure the demand for China’s new crown vaccine in China and other countries in the world. ” On the 20th, at a press conference on the Joint Prevention and Control Mechanism of the State Council, Zheng Zhongwei, leader of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, and director of the Research Center for the Development of Medical Science and Technology of the National Health Commission, he said.
According to Tian Baoguo, deputy director of the Department of Science and Technology of Social Development of the Ministry of Science and Technology, the research and development work of China’s new crown vaccine is currently in a leading position, and 13 of them have entered the clinical stage. Among them, two technical routes of inactivated vaccine and adenovirus vector vaccine, a total of 4 vaccines, have entered phase III clinical trials. All four vaccines that have entered phase III clinical trials are generally progressing smoothly. So far, a total of approximately 60,000 subjects have been vaccinated and no serious adverse reactions have been reported, initially showing good safety.
At present, China has carried out an emergency use of vaccines in some populations. In response, Zheng Zhongwei said that the use of emergency vaccines among high-risk groups is a much-needed means of protecting their lives and health.
In fact, the price is also of great concern to the public. In this regard, Zheng Zhongwei pointed out that (the price of the new crown vaccine) online rumors are all false reports, and most of them are taken out of context. The price of the new corona vaccine is not based on supply and demand, but on cost. The price of the new corona vaccine must be within the range of public acceptance.
Production capacity can reach 610 million doses by the end of the year
The National Health Commission affirmed that we must fully understand the arduous and complex task of our country of “entry of external defense and rebound of internal defense”, continue tightening the chain of prevention and control of epidemics and overcome paralyzing thoughts , lax emotions, the exhaustion of war and the relaxation mindset. Strictly implement foreign import prevention measures, resolutely curb the spread of the local epidemic of pneumonia of the new crown, and prevent the emergence of clusters to the greatest extent possible.
The vaccine will play a key role in curbing the epidemic and all countries are accelerating research and development. Liu Jingzhen, president of Sinopharm Group also stated that at present, the two inactivated vaccines, the Beijing Institute of Biological Products and the Wuhan Institute of Biological Products, which are affiliated with Sinopharm Sinopharm, are now being launched in 10 countries, including the United Arab Emirates, Jordan, Peru, Argentina, and Egypt. In clinical trials, more than 50,000 people have been inoculated.
Zheng Zhongwei said that the new corona pneumonia epidemic is an unprecedented global pandemic of infectious diseases. Recently, there has been another outbreak or rebound of the epidemic in some countries and regions. For our country, it is facing enormous import pressure from the new corona epidemic.
“In this process of dealing with the pressure of foreign imports and the pressure of the domestic rebound, some people in our country have become high-risk exposure groups during the anti-epidemic process, such as medical defense personnel in the first line of the anti-epidemic, the personnel in the border ports and due to work The reason is that the personnel who must go to high-risk countries or regions for assistance, as well as the guarantee personnel of the public service that maintains the basic functioning of the city, they are all facing the risk of contagion. Therefore, the emergency use of vaccines among these people is to protect them. Life, health and safety are very necessary means, “said Zheng Zhongwei.
Zheng Zhongwei said that the emergency use of the new corona vaccine in China is based on this basis and is initiated in strict accordance with the relevant provisions of the “Vaccine Administration Law of the People’s Republic of China” and the ” Drug Administration Law of the People’s Republic of China, “and has gone through layers The strict demonstration and approval have also met the relevant standards of the World Health Organization. After obtaining approval for emergency use of the new vaccine from China crown, China also notified the representative office of the World Health Organization in China, and received their approval and support.
Zheng Zhongwei went a step further, saying that in the process of advancing the emergency use of the new corona vaccine, China has carried out very strict expert argumentation and selected the emergency vaccine. China’s emergency vaccines have completed phase I and phase II animal trials and clinical trials in strict accordance with relevant regulations, and phase I and phase II trials have also achieved very good safety indicators and immunogenicity indicators. Additionally, prior to the official launch of the emergency use of the new corona vaccine, the preferred vaccine for phase III clinical trials was approved. From today’s point of view, large-scale population data from China’s phase III clinical trials have once again verified the safety and some efficacy of the emergency use of the new corona vaccine in China.
Furthermore, during the emergency use of the new corona vaccine, China strictly followed the approved plan, organized and implemented it on the premise of voluntary, informed consent and consent, and established very strict recipient screening, adverse reaction monitoring. and emergency treatment. , Work plan for follow-up after vaccination. So far, during the emergency use of the new corona vaccine in China, all staff have reported no serious adverse reactions and some people working in high-risk areas have reported no infections.
While paying attention to the epidemic in China, China is also paying attention to the development of the global epidemic, so that developing countries can also use and pay for safe and effective vaccines.
Zhao Xing, a second-level inspector of the International Department of the Ministry of Foreign Affairs, said that China has joined the “New Coronary Pneumonia Vaccine Implementation Plan” co-sponsored by the WHO World Vaccine Alliance. This is also China’s adherence to the concept of a human health community and promoting vaccines to go global A major public products initiative, joining the implementation plan has also received wide support and praise from the international community . “China has solemnly promised that once China’s vaccine research and development is completed and put into use, priority will be given to developing countries as a global public product. This is also consistent with the objectives and the original intentions of the implementation plan. “
Zheng Zhongwei said that by the end of this year, the annual production capacity of China’s new crown vaccine will reach 610 million doses. Next year, the annual production capacity of the new Chinese crown vaccine will be effectively expanded on this basis to effectively ensure the demand for the new Chinese crown vaccine in China and other countries in the world.
Cost based pricing
As the large-scale launch of the vaccine approaches, the public is particularly concerned about whether the new corona vaccine can be included in health insurance and how to price it. Various versions of pricing have also appeared online.
Earlier, a representative of the National People’s Congress made the suggestion that “the new vaccination against coronary pneumonia should be included in the total reimbursement of medical insurance.
In response to this suggestion, the National Medical Security Administration recently published the “Response to Recommendation No. 9354 of the third session of the 13th National People’s Congress” (hereinafter the “Response”) on its official website, stating that the level of funding for China’s basic health insurance is particularly urban and rural. The level of funding for resident health insurance is relatively low. In 2019, the per capita funding for health insurance for urban and rural residents was only 800 yuan. However, the number of people for vaccination was high and the total cost required was high, which obviously exceeded the capacity of the health insurance fund.
The “Vaccine Management Law of the People’s Republic of China” implemented on December 1, 2019 shows that China divides vaccines into immunization programs and non-immunization programs. The “Interim Measures for the Administration of Basic Health Insurance Medicines”, published in July 2020, clearly established that preventive vaccines are not included in the scope of health insurance payments.
Prior to this, Liu Jingzhen, secretary of the Party Committee and chairman of Sinopharm Group, said in an interview with the media that after the third phase of the international clinical trial, the new inactivated corona vaccine may enter the approval process, it is expected to be launched at the end of December this year, and revealed that the inactivated vaccine will be on the market. Later, the price will not be very high, it is expected to be several hundred dollars a needle. If you get two shots, the price should be within 1,000 yuan.
In the public health and epidemic prevention zone of the Trade and Services Fair, not long ago, Yin Weidong, Kexing Biotech Chairman, Chairman and CEO, also said that due to different buyers and different purchasing scales, the price of the vaccines will fluctuate to some extent, but the final price will be 100 yuan. , It will not exceed 1,000 yuan.
Zheng Zhongwei said that the price version circulating on the Internet is not true. The price of China’s new crown vaccine first adhere to the price of the main body of the company, while adhering to several basic principles: one is the principle of the public attributes of the product. The price should not be based on supply and demand, but on cost. The second is to carry out the pricing of the new corona vaccine in accordance with the will and demand of the public for a new corona vaccine.
Zheng Zhongwei said that the price of the new corona vaccine should be within the acceptable range of the public. He emphasized that there are many factors that determine the price of the new corona vaccine, including cost, production capacity, inoculation scale, etc., and the cost of the different technical routes is also different. For example, the production of inactivated vaccines requires high-level biosafety production workshops and the cost is relatively high. Adenovirus vector vaccines The cost of such vaccines will be relatively low and with the expansion of production capacity and inoculation scale, the cost will also change.
(Author: Zhu Ping publisher: Fang Ming package)
